FY 2020 results webcast

19 February 2021

Galápagos
Pioneering for patients

Disclaimer

This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, our expectations regarding commercial sales of Jyseleca, the global R&D collaboration with Gilead, the amendment of our arrangement with Gilead for the commercialization and development of Jyseleca, the timing and/or outcome of the strategic re-evaluation and the cash burn guidance 2021, statements relating to interactions with regulatory authorities, the potential approval process for filgotinib in RA, UC and additional indications, such additional regulatory authorities requiring additional studies, the outcome of pricing and reimbursement interactions, statements relating to the build-up of our commercial organization for filgotinib, statements regarding data from Galapagos' clinical research programs with ziritaxestat which may not support registration or further development due to safety, efficacy or other reasons for IPF, SSc or any other indication, the expected impact of COVID-19, and our strategy, business plans and focus, the slides captioned "ISABELA discontinued," "Deep R&D portfolio based on novel targets," "Broad pipeline," "Building our European commercial footprint," "Outlook," statements regarding the expected timing, design and readouts of ongoing and planned clinical trials (i) with filgotinib in RA, UC, IBD, and other potential indications (ii) with GLPG1205 and GLPG4716 in IPF, (iii) with the Toledo program (iv) with GLPG3667 in Pso, (v) with GLPG0555 in OA, expectations regarding the commercial potential of our product candidates, and our strategy, business plans and focus. When used in this presentation, the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "will," "plan," "potential," "possible," "predict," "objective," "should," and similar expressions are intended to identify forward-looking statements.

Except for filgotinib's approval for the treatment of RA by the European Commission and Japanese Ministry of Health, Labour and Welfare, our other drug candidates mentioned in this presentation are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority and they are not yet approved for any use outside of clinical trials.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements (including that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, including ziritaxestat for IPF, SSc or any other indication and the uncertainties relating to the impact of the COVID-19 pandemic), reliance on third parties (including Galapagos' collaboration partner Gilead) and estimating the commercial potential of its product candidates, including Galapagos' estimates regarding the commercial potential of ziritaxestat, and the possibility that Galapagos and Gilead may make a strategic decision to discontinue development of ziritaxestat and that ziritaxestat may as a result never be successfully commercialized. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission ("SEC") filing and reports, including Galapagos' most recent Form 20-F and subsequent filings with the SEC. Given these uncertainties, you are advised not to place any undue reliance on such forward-looking statements.

All statements herein speak only as of the release date of this document. Galapagos expressly disclaims any obligation to update any statement in this document to reflect any change in future development with respect thereto, any future results, or any change in events, conditions and/or circumstances, on which any statement is based, unless specifically required by law or regulation.

Under no circumstances may any copy of this presentation, if obtained, be retained, copied, or transmitted.

ISABELA discontinued

- Dose dependent mortality
- Efficacy below expectations
- All activities with ziritaxestat discontinued
- IPF pipeline: 4 development programs aimed at fibrosis

We remain committed to IPF and fibrosis

2020 in review

Q2	Q3	Q4		
Jyseleca positive UC Ph3 results	Jyseleca approved & launched in EU & JP in RA	ROCCELLA in OA fails	OncoArendi	Updated agreement Jyseleca EU
	CRL filgotinib RA	Filing Jyseleca in UC EU	Fidelta sold	
		Toledo Roundtable	Start 3 PoC SIK2/3 GLPG3970	
		Start Ph1b with TYK2 psoriasis	PINTA positive IPF	

Inflammation Fibrosis Corporate development

Galápagos

Deep R&D portfolio based on novel targets

27
validated targets

13
programs in LO

3
preclinical candidate programs

10
clinical stage programs

** LO: Lead optimization*

Galápagos

Broad pipeline



Galápagos

Building our European commercial footprint

- NICE (UK) recommendation moderate RA
- Germany launch on track
- Reimbursement process other countries ongoing
- Complete transition by YE

Galápagos

Cash & current financial investments



Cash burn €517M; cash position ~€5.2B end of 2020

Galápagos

Key financials FY ’20

Revenues: €530.3M (*)

- €228.1M revenue recognition for filgotinib + €16.2M royalties,
- €229.6M revenue recognition for the platform

Operating costs: - €708.9M (*)

- Increase driven by filgotinib, Toledo and S,G&A

Net loss: - €305.4M

- €134.2M net other financial expense

(*) Continuing operations (excluding Fidelta)

Galápagos

Outlook

Filgotinib

- Filing UC Japan
- Outcome MANTA/RA-y
- EU approval decision UC
- DIVERSITY recruited CD

Readouts

- Toledo POCs Pso/RA/UC
- ‘3667 (TYK2) Ph1b Pso
- ‘555 (JAK1) Ph1b OA

Cash burn guidance 2021 under review

Q&A

Galápagos

Pioneering for patients


Galápagos